We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.00 | -1.07% | 92.08 | 92.05 | 92.07 | 94.03 | 92.00 | 93.99 | 247,814 | 09:20:26 |
By Cecilia Butini
Sanofi SA said Tuesday that it won't further advance the development of a messenger-RNA vaccine against Covid-19 and would instead focus on another type of shot, despite reporting positive interim results in a phase 1/2 mRNA trial.
The French pharma major said it wouldn't make sense for it to advance its mRNA vaccine into a phase 3 trial. "From a public-health perspective, mRNA Covid vaccines are widely available today and starting a placebo-controlled study in countries where vaccines are available would be extremely challenging, so it does not make sense for us to further advance our mRNA Covid vaccine into Phase 3," a company spokesman said.
The company had said earlier Tuesday that a phase 1/2 trial for a mRNA vaccine against the coronavirus showed neutralizing antibodies in 91% to 100% of study participants two weeks after a second injection.
Sanofi's work on Covid-19 will now be focused on a vaccine which uses an adjuvanted recombinant protein technology and which it is developing in partnership with GlaxoSmithKline PLC, it said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 28, 2021 04:57 ET (08:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions